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Ear and kidney syndromes: Molecular versus clinical approach.
The association between ear and kidney anomalies is not usually
due to an insult to the embryo. In recent years, many essential
development control genes that coordinate the assembly and
function of kidney and ear have been discovered through the
generation of animal mutants and have increased our under-
standing of the mechanisms of human oto-renal diseases. Here,
we describe ear and kidney clinical syndromes and their molec-
ular expression.
First ear and kidney abnormalities were reported in
1946 by Edith Potter’s association of crumpled and
flattened ears with bilateral kidney agenesis [1]. Ear
malformations are associated with an increased fre-
quency of clinically significant structural renal anoma-
lies compared with the general population. These include
specific multiple congenital anomaly syndromes, Townes-
Brocks syndrome (TBS), branchio-oto-renal (BOR) syn-
drome, among others. Many studies in the literature have
noted a significant association between renal anomalies
and various ear anomalies. Ear pits and tags, perhaps the
most common minor ear malformations, occur with a fre-
quency of five to six per 1000 live births [2, 3]. In the
pediatric population, structural renal anomalies occur in
one to three per 100 live births [4]. Children who had
isolated preauricular tags presented on renal ultrasonog-
raphy urinary tract abnormalities in 3% to 8% of cases
as hydronephrosis, horseshoe kidney, kidney agenesis, or
hypoplastia [5, 6]. A recent study [7] of 32,589 consecutive
live births, still births, and abortions over 10 years in the
Mainz Congenital Birth Defect Monitoring System noted
a 1.2% prevalence of renal anomalies. After patients with
syndromic diagnoses were excluded, auricular pits or cup
ears and specific renal anomalies were still associated [7].
Half a century later, ear and kidney development has
been characterized in great detail, demonstrating that
embryologically, ear and kidney primordia arise at differ-
ent times and develop at different rates (Fig. 1). There-
fore, the association between ear and kidney anomalies
is usually not due to an isolated insult to the embryo that
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would affect both developing structures at the same time.
The genes responsible for hereditary deafness in humans
and in vertebrate model systems have been recently iden-
tified. These serve as useful molecular markers, but more
important, a number of these genes undoubtly play key
roles in kidney and ear determination. Table 1 summa-
rizes the findings in the various model systems to date. Re-
cent identification of genes that are responsible for BOR
syndrom and TBS, along with gene expression studies of
these genes, has shown that these genes were expressed
in developing ear and kidney structures at different times
during morphogenesis [8].
EAR ANATOMY
The ear is the organ of hearing and balance and consists
of three parts: the outer ear, the middle ear, and the inner
ear. The outer ear and middle ear are the apparatus for
the collection and transmission of sound. The inner ear is
responsible for analyzing sound waves, and also contains
the mechanism by which the body keeps its balance. The
outer ear is comprised of the pinna and ear canal; the mid-
dle ear includes the eardrum, hammer, anvil, stirrup, and
eustachian tube; and the inner ear includes the vestibule,
semicircular canals, and cochlea. Sensory impulses from
the inner ear pass to the brain via the vestibulocochlear
nerve.
Outer ear
The outer ear consisting of the pinna (also called the
auricle) is the visible part of the ear and is composed of
folds of skin and cartilage. The pinna leads into the ear
canal (also called the meatus) and is about 1 inch (or
2.5 cm) long in adults and closed at its inner end by the
tympanic membrane or (eardrum). The part of the canal
nearest the outside is made of cartilage. The cartilage is
covered with skin that produces wax, and the tiny hairs in
the canal traps dust, pollen, pollution, and small foreign
bodies.
Middle ear
The middle ear is a small cavity between the eardrum
and the inner ear. It conducts sound to the inner ear by
means of a chain of three tiny, linked, movable bones
called ossicles. They link the eardrum to an oval window
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Fig. 1. Ear and kidney embryology.
in the bony wall on the opposite inner side of the middle
ear cavity. The bones are named because of their shapes.
The malleus, or hammer, is joined to the inside of the
eardrum. The incus, or anvil, has one broad joint with
the malleus (which lies almost parallel to it) and a del-
icate joint to the third bone, the stapes, or stirrup. The
base of the stapes fills the oval window, which leads to
the inner ear. The middle ear is cut off from the outside
by the eardrum, but it is not completely airtight. A ven-
tilation passage, called the eustachian tube, runs forward
and down into the back of the nose. The eustachian tube
is normally closed, but it opens by muscular contraction
when yawning and swallowing. The middle ear acts as a
transformer. It passes the vibrations of sound from com-
pression and decompression of the outside air. The air
is a thin medium that carries the sound into the inner
ear where the fluid in the inner ear, a thicker medium,
resonates the sound vibration.
Inner ear
The inner ear is an extremely intricate series of struc-
tures contained deep within the bones of the skull. It
consists of a maze of winding passageways, collectively
known as the labyrinth. The front part, the cochlea, is a
tube resembling a snail’s shell and is related to hearing.
The rear part, which is three semicircular canals and two
other organs, is concerned with balance. The semicircular
canals are set at right angles to each other and are con-
nected to a cavity known as the vestibule. These canals
contain hair cells bathed in fluid. Some of these cells are
sensitive to gravity and acceleration and others respond
to head positions and movement (side to side, up and
down, or tilted). Posture or direction information is reg-
istered by the relevant cells and conveyed by nerve fibers
to the brain.
The ear is susceptible to a large number of disorders,
some of which can lead to deafness.
FOCUS ON EAR AND KIDNEY EMBRYOLOGY:
MOLECULAR MECHANISMS AND
GENE EXPRESSION
The embryogenesis of the association of renal and au-
ricular anomalies is unclear. The combination of ear and
kidney anomalies in the early stages of development can
be explained on the assumption that mesodermal induc-
tion (transcription factor, gene expression) is responsible
for normal differentiation of both organs. However, in the
late stages of development, those factors only intervene
in the inner ear function (Fig. 2).
Organogenesis involves many cellular processes, such
as proliferation, cell adhesion, apoptosis, cell differentia-
tion, cell migration, all of which require molecules from
different classes and family. In recent years, many es-
sential developmental control genes that coordinate the
assembly and function of kidney and ear have been dis-
covered through the generation of animal mutants and
have increased our understanding of the mechanisms of
epithelial interactions.
Transcription factors, growth factors, and their recep-
tors that are essential for both ear and kidney develop-
ment are discussed and their functions and phenotype are
summarized in Tables 1 and 2, respectively:
Pax-Six-Eya-Dach signaling network
A number of transcription factors are expressed in
the presumptive otic ectoderm, but two of the earliest
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Table 1. Ear and kidney genes’ functions
Ear and kidney genes’ functions
Genes Ear Kidney
Glial cell-line–derived
neutrophic factor
Protects hair cells from damage Essential for ureteric bud growth and branching
morphogenesis of the ureteric bud epithelium
Fibroblast growth factors Induces both the otic placode and the epithelial
organization of the otic vesicle
Maintains the nephrogenic mesenchyme; induces its
condensation and autocrine secretion of Wnt-4
converts it to epithelium
Bone morphogenic proteins Proteins emanating from the otic epithelium influence
chondrogenesis of the otic capsule, including the
cartilage surrounding the semicircular canals
Modulate ureteric bud branching and keep bud
development in step with that of other tissue types
Wnt signaling and Frizzled
receptors
Could be involved in several aspects of late cochlear
differentiation and/or auditory function
Critically required for tubulogenesis in the
pronephric kidney
GATA3 Repressor of critical genes involved in cell
differentiation in the organ of corti
Intervenes at the interface of Wolffian duct and the
metanephric blastema at about 7 weeks gestational
age
Parchorin Generally plays a critical role in water-secreting cells,
possibly through the regulation of chloride ion
Prestin Required for electromotility of the outer hair cell and
for the cochlear amplifier; the motor protein of the
cochlear outer hair cell
Atrial natriuretic peptide May be involved in fluid homeostasis in the inner ear
and the kidney
Barttin Crucial for renal salt reabsorption and potassium
recycling in the inner ear
Increases surface expression and changes current
properties of ClC-K channels and is required for
adequate tubular salt reabsorption
ATP6B1 Role in endolymph pH homeostasis and in normal
auditory function
Role in normal vectorial acid transport into the urine
by the kidney encoding the B-subunit of the apical
proton pump mediating distal nephron acid
secretion
Gyro Intervenes on renal excretion of phosphate, and
impairment of Na+/phosphate cotransport by renal
brush-border membrane vesicles
KCNQ May be present in amniote vestibular hair cells;
destabilization of the resting potential and increase
in [Ca2+]i, as may result from impaired KCNQ4
function in IHCs, whereas mutations in KCNQ1
causes deafness by affecting endolymph secretion,
the mechanism leading to KCNQ4-related hearing
loss is intrinsic to outer hair cells
AQP-2 Role in the development of endolymph homeostasis Regulated urinary diluting ability; important for
rapid near-isosmolar transepithelial fluid
absorption/secretion and for rapid vectorial water
movement driven by osmotic gradients
Mpv17 Peroxisomal protein involved in the metabolism of
reactive oxygen species; the severe sensorineural
hearing loss and degenerative changes of the
cochlear structures indicate that cochlear
structures, especially the outer hair cells and the
intermediate cells of the stria vascularis, are
vulnerable to the missing Mpv17 gene product;
both organs have specialized epithelia involved in
active ion transport, which are separated from the
vessels by a basement membrane of similar
composition; glomerular and the stria vascularis
basement membrane are simultaneously affected in
early stages
genes activated in the presumptive otic ectoderm are
the transcriptional regulators Pax8 (OMIM 167415) and
Pax2 (OMIM 167409) [9–11]. Other transcriptional reg-
ulators expressed in preplacode otic ectoderm include
members of the Six, Eya, and Dach gene families,
defined as a Pax-Six-Eya-Dach synergistic regulatory
network involved in the formation of a number of or-
gans. Metanephric kidney development begins with the
formation of the metanephrogenic mesenchyme; this
event depends on the prior action in the intermedi-
ate mesoderm of transcription factors such as Pax2 and
Eya1.
Six1 (OMIM 601205) and Six4 (OMIM 606342) are
expressed in the developing inner ear. Expression of Six
genes is also seen in the individual otic placodes in the
Xenopus, chick, and mouse [12–16].
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Fig. 2. Focus on anatomy, physiology, and cell biology.
In the embryonic human kidney, the EYA1 gene is
expressed strongly, and in the BOR syndrome there is
an inductive fault between the ureteric bud and the
metanephric mesenchymal mass as the ureteric bud
branches into the renal parenchyma. Eya4 is also thought
to have a role in ear formation, as its expression has been
reported in neuroepithelia of rat inner ear from E14.5
onwards, and loss of Eya4 in humans causes deafness
[17, 18].
Dach proteins (OMIM 603803) have shown to have
direct protein-protein interactions with Eya family mem-
bers [19] and epistatic analyses in Drosophila have posi-
tioned dachshund (dach)—the Drosophila homologue of
the vertebrate Dach genes—downstream of eya. During
ear development, Dach1 overlaps with Eya1 and Pax2 ex-
pression but Dach1 expression does not depend on these
genes, as its early expression is not affected in the null
mutants.
Glial cell-line–derived neutrophic factor
Glial cell-line–derived neutrophic factor (GDNF) en-
codes a member of the transforming growth factor-b
(TGF-b) family of signaling molecules, which has an
important role in ureteric-bud induction. Its loss in
gdnf-knockout mice leads to the failure of ureteric-bud
formation [20].
SALL1
Sall1 is a mammalian homologue of the Drosophilia
region-specific homeotic gene splat. Sall1 is expressed in
the kidney mesenchyme and its inactivation leads to in-
complete ureteric-bud growth and to the failure of tubule
formation [21]. Heterozygous SALL1 mutations in hu-
mans lead to TBS.
Fibroblast growth factors
Fibroblast growth factor (FGF) receptors (FGFRs)
were localized to all nephron and collecting duct epithe-
lia. FGFR-1 and FGFR-3 were localized to glomeruli,
FGFR-3 to proximal tubules and FGFR-1 to thin limbs.
FGFR-1 through FGFR-3 was localized to distal straight
tubules, with FGFR-1 and FGFR-3 localized to distal con-
voluted tubules. FGFR-1 and FGFR-3 were localized to
medullary collecting ducts. In addition, FGFR-1 was lo-
calized to the smooth muscle of renal arteries. All FGFR
variants were expressed in the cortex and outer medulla,
with fewer FGFRs in the inner medulla. FGF-1, FGF-2,
FGF-7, FGF-8, and FGF-9 were expressed in the kidney,
with FGF-10 expression found only in the cortex. [21].
Experiments by Represa et al [22] implicated FGFs as
having an important early role in ear formation. Deple-
tion of Fgf3 in explants by antisense nucleotides and an-
tibodies prevented the formation of ear vesicles, whereas
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the application of Fgf2 was shown to rescue otic vesi-
cle induction in explants where the hindbrain had been
removed. A later role for Fgf3 signaling in inner ear
formation was postulated given that homozygous Fgf3
knockout mice had severe ear malformations where
the endolymphatic duct failed to form correctly but
still formed ear vesicles [23]. Very recently, Dode et al
[24] established that loss-of-function mutations in FGFR-
1 underlie KAL2 whereas a gain-of-function muta-
tion in FGFR-1 has been shown to cause a form of
craniosynostosis.
Bone morphogenic protein
Bone morphogenic proteins (BMP) have recently
emerged as likely regulators of development of the per-
manent kidney (metanephros). Transcripts for BMPs and
their receptors have been localized in the developing
metanephros, but BMP7 is the only Bmp that is expressed
in the nephrogenic mesenchyme [20]. In vitro, BMP2, 4,
and 7 have direct or indirect roles in regulation of ureteric
branching morphogenesis and branch formation. In vivo,
renal phenotypes have been reported in BMP7 homozy-
gous null mutant mice and BMP4 heterozygous null mu-
tant mice. In vitro, high concentrations of BMP4 inhibited
branching of the ureteric epithelium and changed its mor-
phology, while nephrogenesis was inhibited by 50% [25].
BMP4 (OMIM 112262) may be a physiologic regulator
of the development of the periureteric smooth muscle
layer and ureteric elongation. [26]. Furthermore, BMP4
predominantly inhibits neural differenciation in early de-
velopment. The vertebrate inner ear consists of a complex
labyrinth of epithelial cells that is surrounded by a bony
capsule. BMP proteins are important for the develop-
ment of the otic epithelium in the chicken inner ear and
possibly acting through BMP receptors IB (BMPRIB)
are important for otic capsule formation. In addition,
BMPs and their receptors influence chondrogenesis of
the otic capsule, including the cartilage surrounding the
semicircular canals [27].
Wnt signaling and frizzled receptors
Wnts are a large family of secreted signal that regulate
key morphogenetic steps during embryogenesis. Frizzled
proteins have been identified as likely receptors for Wnt
ligands in vertebrates and invertebrates. Wnt-4 (OMIM
603490) is critical for genitourinary development but
found only in the most distal collecting duct epithelium
in the normal murine adult kidney. Wnt-4 expression co-
incided with mesenchyme-to-epithelium transformation.
In the metanephric kidney, Wnt-4 is critically required
for tubulogenesis in the pronephric kidney [28]. Wnt-4 ex-
pression is induced throughout the collecting ducts in four
murine models of renal injury that produce tubulointer-
stitial fibrosis: folic acid-induced nephropathy, unilateral
ureteral obstruction, renal needle puncture, and polycys-
tic kidney disease [29]. The expression of various compo-
nents of the Wnt signaling pathway has been observed in
the developing inner ear [30–33]. Wnt-4 and frizzled gene
families are in the postnatal rat cochlea [34].
GATA3 (OMIM 131320)
Recently, a member of the GATA-binding family of
transcription factors was shown to be involved in the hu-
man hypoparathyroidism, sensorineural deafness and re-
nal anomalies (HDR) syndrome. The HDR phenotype is
consistent with the expression pattern of GATA3 during
human and mouse embryogenesis in the developing kid-
ney (ureteric bud, collecting duct system, and mesangial
cells), otic vesicle, and parathyroids. Terminal deletions
of chromosome 10p result in that those studies in patients
with 10p deletions have defined two nonoverlapping re-
gions that contribute to the complex phenotype (includes
hypoparathyroidism, heart defects, immune deficiency,
deafness, and renal malformations or DiGeorge-like syn-
drome). These are the DiGeorge critical region II, which
is located on 10p13-14, and the region for the HDR syn-
drome (Mendelian Inheritance in Man number 146255),
which is located more telomeric (10p14-10pter) [35]. The
apparently selective GATA3 is further expressed in the
developing spiral sensory neurons [36–38].
a8/b1 integrin
ITGA8 (604063). Using immunohistochemistry,
Muller et al [39] demonstrated that in mouse, a8/b1
integrin is expressed in many developing organs and par-
ticularly in the kidney, in mesenchymal cells bordering on
epithelial cell sheets that undergo branching morphogen-
esis. By gene targeting, they produced mice lacking the a8
gene. The mutant mice showed severe deficits in kidney
morphogenesis due to reduced growth of the ureteric bud
toward the metanephric mesenchyme, reduced branch-
ing of the ureteric epithelium within the mesenchyme,
and defective epithelialization of kidney mesenchymal
cells. The authors [39] concluded that a8/b1 integrin plays
a crucial role in epithelial-mesenchymal interactions dur-
ing kidney morphogenesis. Mechanosensory hair cells
within the neuroepithelia of the cochlea and vestibule
have stereocilia that are indispensable for mechanosen-
sation. Evans and Muller [40] demonstrated that a8/b1
integrin, its ligand fibronectin (135,600), and the integrin-
regulated focal adhesion kinase (600,758) colocalize to
the apical hair cell surface where stereocilia are forming.
In mice homozygous for a targeted mutation of a8/b1
integrin, the colocalization is perturbed, and hair cells in
the utricle, a vestibular subcompartment, lack stereocilia
or contain malformed stereocilia. Most a8/b1 integrin-
deficient mice die soon after birth due to kidney defects.
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Many of the surviving mice have difficulty balancing,
consistent with the structural defects of the inner ear.
The authors [40] concluded that a8/b1 integrin and po-
tentially other integrins regulate hair cell differentiation
and stereocilia maturation.
The transcription factor FKH10 of the forkhead family
Forkhead(Fkh) box 10 is expressed in the kidney mes-
enchyme and might function to locate the site where the
ureteric bud forms on the Wolfian duct [20]. Although
Fkh10 may play a role in the kidney during later stages of
development, it may be a minor, or perhaps redundant,
role, as no kidney dysfunction was observed in homozy-
gous knockout mice. On the contrary, Fkh10 appears to be
unique in the sense that it is an early otic vesicle-specific
gene necessary for the development of both cochlea and
vestibulum. These findings implicated Fkh10 as an early
regulator necessary for development of both cochlea and
vestibulum and identified its human homolog FKHL10
FKHL10 as a previously unknown candidate deafness
gene at 5q34. The phenotype described by Hulander
et al [41] resembles a group of human congenital inner ear
malformations called “common cavity.” The authors pro-
posed that mutations in FKH10 may cause a “common
cavity” phenotype in humans.
Subtype mitochondria-rich cells
Subtype A mitochondria-rich cells, from which pro-
truding A mitochondria-rich cells are the activated state,
are involved in proton secretion [apical H+-adenosine
triphosphatase ATPase)] and thus are potential candi-
dates for hearing loss accompanying renal tubular aci-
dosis. Subtype B mitochondria-rich cells are the most
likely candidates to be affected in Pendred syndrome
because of the assumed function of pendrin as apical
Cl−/HCO3−exchanger [42].
Ear and kidney fluid homeostasis
Parchorin, a new chloride intracellular channel fam-
ily member, preferentially resides in the epithelium of
the ducts of the lacrymal, parotid, submandibular, and
mammary glands and the pancreas, prostate, testis, and
eye. In the kidney, parchorin was distributed mainly from
the thick ascending limb to the distal convoluted tubule.
Parchorin was also present in the cochlea and semicir-
cular canal. The cellular distribution and changes in ex-
pression indicate that parchorin plays an important role,
possibly in chloride transport, in the cells that create an
ion gradient for water movement [43].
Prestin is a gene recently cloned from mammalian
cochlear outer hair cells (OHC) using a single cell type,
outer minus inner hair cell, specific suppressive substrac-
tive hybridization procedure. The localization and gene
expression profile of the prestin protein fits the pattern of
OHC’s development of electromotility. When prestin is
abundantly expressed in normally nonmotile kidney cells,
nonlinear capacitance and motility that are normally only
seen in OHCs can be recorded. Furthermore, both non-
linear capacitance and motility can be reduced by salicy-
late, a well-known inhibitor of electromotility. Prestin is
the fifth member of a newly discovered anion transport
family (SLC26), which are chloride-iodide transporters,
Cl−/HCO3− exchangers or sulfate transporters [44].
The atrial natriuretic peptide (ANP) receptors are
found within the human endolymphatic sac (ELS), with
a predominance of ANP type B based on the intensity of
staining. The ANPs may be involved in fluid homeostasis
in the inner ear. Based on these findings, C-type natri-
uretic peptide may be a more effective peptide within
the human ELS for fluid regulation because its binding
affinity is virtually exclusive for the ANP type B receptor
[45].
CLINICAL APPROACH OF THE
OTO-RENAL SYNDROMES
Renal dysplasia or urinary tract anomalies
and hearing loss
BOR syndrome. Although the association of
branchial arch anomalies and hearing impairment has
been known since the nineteenth century, the syndrome
was first outlined in 1975 [46]. The incidence of BOR syn-
drome is 1:40,000 and has been reported to occur in 2%
of profoundly deaf children [47]. Typical signs are hear-
ing impairment, ear malformations, branchial cleft, and
renal abnormalities. The clinical expression of the BOR
syndrome gene is extremely variable from one family to
the next [48–51]. Clinical studies suggest that there are at
least three distinct syndromes involved in the branchio-
genic disorders. The first, BOR dysplasia, is associated
with renal anomalies; but the second, BO dysplasia, lacks
renal anomalies; and the third, BR anomalies, results in
branchial and renal disorders with no associated hearing
loss. Otic anomalies affect all three compartments of the
ear (preauricular pits and appendages (77% of cases),
auricular malformations, and atresia to stenosis of the
external auditory canal), cervical fistulas and cysts (63%
of cases) representing developmental defects of the first
branchial arches (for the tympanic cavity), as well as the
first and second branchial arches (ossicular) and the in-
ner ear (absent or underdevelop cochlea and absent or
hypoplastic semicircular canals). Thus, the hearing loss
of the syndrome could be conductive (30%) (caused by
outer and middle ear anomalies), sensorineural (20%)
(caused by inner ear anomalies), or mixed (50%). The
severity of the impairment may differ between the two
ears [10]. Facial nerve paralysis has also been reported
in association [52]. In BOR syndrome middle and inner
376 Izzedine et al: Molecular versus clinical approach
ear defects are commonly ossicular chain malformations
[52] and Mondini dysplasia of the cochlea [52, 53]. The re-
nal defects, estimated to be severe in only approximately
6% of heterozygotes, include collecting system duplica-
tions, renal hypoplasia, cystic dysplasia, and agenesis [47,
54], characterized by decreased renal volume and size,
loss of ultrasound normal corticomedullary differenti-
ation, and hyperechogenecity of the renal cortex. His-
tologically, there is glomerular hyalinization, mesangial
proliferation, and basement membrane splitting [55]. Bi-
lateral renal agenesis is the extreme, leading to mis-
carriage or immediate neonatal death [56]. Other re-
nal abnormalities include hydronephrosis associated with
ureteropelvic junction obstruction or vesicoureteral re-
flux. There can also be bifid kidneys with double ureters
and calyceal anomalies [6]. Other minor renal anoma-
lies were subsequently reported [57, 58] and radiographi-
cally documented in 13% [47]. Similar to BOR syndrome,
Eya1+/− mice also showed renal defects at low pene-
trance, including renal hypoplasia (2/25 in 129 newborns)
and unilateral agenesis (2/11 in BL/6 adult mice). In con-
trast to the low incidence of renal defects in Eya1+/− mice,
all Eya1−/− mice lacked kidneys and ureters due to a fail-
ure of ureteric bud outgrowth and metanephric induction.
[59]. The gene underlying this syndrome, EYA1 (OMIM
601653), is homologous to the Drosophila developmental
gene eyes absent wich encodes a transcriptional coacti-
vator required for eye specification. The first BOR syn-
drome gene has been mapped to chromosome 8q [60, 61];
and the EYA1 gene (homologous to the Drosophila de-
velopmental gene denoted as “eyes absent”) underlying
this syndrome has been identified, and several mutations
have been reported [62, 63]. The EYA1 gene (OMIM
601653) expressed very early, between 4 and 6 weeks of
human development, can be correlated with the branchial
fistulas, sinuses and cysts but not with the outer and mid-
dle ear anomalies. Deafness relates to abnormalities in
the three ossicles of the middle ear derived from the first
and second branchial arches, while the branchial fistulas
relate to abnormalities of the second, third, and fourth
arches. In contrast, Eya1 is expressed during the slightly
more advanced stage of outer and middle ear morpho-
genesis at E13.5, in the mesenchyme adjacent to the first
branchial cleft and surrounding the primordia of the mid-
dle ear ossicles, and in the epithelium of the tubotympanic
recess. During early inner ear development, Eya1 is ex-
pressed in the ventromedial wall of the otic vesicle in the
statoacoustic ganglion, and in the periotic mesenchyme,
consistent with the cochlear anomalies and sensorineu-
ral hearing loss of BOR syndrome. Subsequently, Eya1
expression is observed in the differentiating hair and sup-
porting cells of the sensory epithelia, as well as in the asso-
ciated ganglia, and persists after differentiation has taken
place. Eya1 expression in the condensing mesenchymal
cells of the kidney is consistent with the excretory and col-
lecting system anomalies of BOR syndrome [8]. In the
embryonic human kidney, the EYA1 gene is expressed
strongly, and in the BOR syndrome there is an induc-
tive fault between the ureteric bud and the metanephric
mesenchymal mass as the ureteric bud branches into the
renal parenchyma. Haploinsufficiency for human EYA1,
a homologue of the Drosophila melanogaster gene
eyes absent (eya), results in the dominantly inherited
disorders, which are characterized by craniofacial ab-
normalities and hearing loss with (BOR) or without
[branchio-oto (BO)] kidney defects syndrome [62, 64, 65].
Eya1 heterozygotes show renal abnormalities and a con-
ductive hearing loss similar to BOR syndrome, whereas
Eya1 homozygotes lack ears and kidneys due to defec-
tive inductive tissue interactions and apoptotic regres-
sion of the organ primordia [66]. Inner ear development
in Eya1 homozygotes arrests at the otic vesicle stage.
Deficiency for the Wilm’s tumor gene WT-1 results in
kidney abnormalities similar to those seen in Eya1−/−
mice [67], and WT-1 expression, normally present in the
metanephric mesenchyme and urogenital ridge, was un-
affected in Eya1 mutants. In contrast, expression of the
gene encoding glial-derived neurotrophic factor (Gdnf )
[68, 69], identified as a mesenchyme-derived signal that
acts as a ligand for the c-ret receptor tyrosine kinase ex-
pressed at the tip of the ureteric bud [70–72], was not
detected in Eya1 homozygotes. Thus Eya1 also appears
to operate in the genetic regulatory cascade controlling
ureteric bud outgrowth, upstream of Gdnf . Eya4 is also
thought to have a role in ear formation, as its expression
has been reported in neuroepithelia of rat inner ear from
E14.5 onwards, and loss of Eya4 in humans causes de-
faness [73, 74]. However, some families are not linked
to the EYA1 locus, suggesting that BOR syndromes may
also be due to mutations in genes other than the EYA1
gene.
TBS. Townes and Brocks first described the syn-
drome in 1972 [75] (OMIM 107480), as a rare autosomal-
dominant malformation syndrome with multiple
malformations and variable expression. Diagnostic
criteria suggested for TBS include two or more of the
following: anorectal malformation (47%) (imperforate
anus, anteriorly placed anus, anal stenosis); hand mal-
formations (45%) (preaxial polydactyly, triphalangeal
thumb, bifid thumb); andexternal ear malformation
(71%) with deafness [76] and renal malformations.
Renal ear anal radial (REAR) syndrome has also been
a term used to describe this condition [77]. Intelligence
is usually normal, although mild-to-moderate mental
retardation has been reported [78, 79]. Other clinical fea-
tures include heart (lethal truncus arteriosus, pulmonary
valve atresia) [80] and eye abnormalities (coloboma)
[75]. External ear anomalies in TBS typically include
small ears with an overfolded superior helix and small
anthelix, sometimes cupped, with preauricular tags or
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pits. Other descriptive terms reported for ear shape in-
clude microtia, “satyr” and “lop.” Sensorineural hearing
loss is common in TBS, ranging from mild to profound.
It is usually congenital and primarily sensorineural,
although a small conductive component is often present.
At least in some patients it is progressive, and is worse
in the high frequencies [81]. Structural middle and
inner ear anomalies have been reported and include
hypoplastic malleus head, uncudomalleolar fusion, ab-
normally shaped oval window and incus and anomalies
of the semicircular canals [82, 83]. A high incidence of
genitourinary abnormalities is founds in TBS. These
include unilateral or bilateral hypoplastic or dysplastic
kidneys, horeshoe kidney, renal agenesis, multicystic
kidney, posterior urethral valves, vesicoureteral reflux,
and meatal stenosis [75, 84, 85]. Renal failure or impaired
renal function were common. Several patients have had
renal transplantation [81, 85]. This underscores the need
for renal imaging and monitoring of renal function in
TBS patients. A prominent midline perineal raphe or
bifid scrotum or both is common in males with TBS.
Hypospadias has also been reported [abstract; Friedman
PA et al, Am J Hum Genet 41 (Suppl):A60, 1987]
[81, 84].
TBS is caused by a defect in the gene encoding the
SALL1 putative transcription factor, a protein possibly
required for urologic, renal, limb, ear, brain, and liver
development. SALL1 was mapped to 16q12.1 [abstract;
Friedman PA et al, Am J Hum Genet 41 (Suppl):A60,
1987]. It is caused by mutations in a putative C2H2 zinc-
finger transcription factor [86]. In the forelimb, SALL1
haplo insufficiency in the most severe cases leads to addi-
tional triphalangeal thumbs, which resemble fingers more
than thumbs. SALL1 could therefore function as a di-
rect or indirect repressor of joint formation and finger
outgrowth. Because most duplications do not involve
metacarpal bones, SALL1 seems to be especially impor-
tant for the later steps in distal limb differentiation and
thumb specification during the seventh to eighth weeks of
embryonic development. SALL1 may be required during
later steps in development of the outer, middle and inner
ear—more specifically, for differenciation of the first and
second branchial arches and for differenciation of the
otic vesicle. SALL1 therefore seems to be required for
some of these steps during the fifth to eighth week of em-
bryonic development [86]. Renal agenesis or multicystic
kidneys represent the most severe kidney anomalies in
TBS. Renal agenesis is thought to result from insufficient
outgrowth of the ureteric buds, whereas multiple cysts
can develop due to either failure of nephrons to contact
the collecting tubules or failure of superfluous tubules to
degenerate or malformation of collecting tubules.
Okihiro syndrome. Okihiro syndrome refers to the
association of forearm malformations with Duane syn-
drome of eye retraction. Specifically, there is overlap
of clinical features with other conditions, most notably
Holt-Oram syndrome, a condition resulting from muta-
tion of the TBX5 locus and TBS, known to be caused by
mutations in the SALL1 gene. Kohlhase et al [87] have
characterized the human SALL4 gene on chromosome
20q13.13-q13.2.
Kallmann-De Morsier syndrome. Kallmann syn-
drome is a developmental disease characterized by
gonadotropin-releasing hormone (GnRH) deficiency
and olfactory bulb hypoplasia. The gene underlying the
X chromosome-linked form, KAL-1, has been identified
for several years that encoded protein, anosmin-1, is a
transient and regionally restricted component of extra-
cellular matrices during organogenesis in man. Anosmin-
1 (OMIM 308700) was detected in the basement
membranes and/or interstitial matrices of various struc-
tures, including mesonephric tubules and duct, branches
of the ureteric bud, and inner ear [88].
Kallmann syndrome refers to the association of
hypogonadotrophic hyogonadism with anosmia (or
hyposmia). The anosmia has been related to the ab-
sence or hypoplasia of the olfactory bulbs and olfac-
tory tracts [89]. Three different modes of inheritance
have been reported in familial cases in Kallmann syn-
drome, X chromosome-linked (KAL-1, OMIM 308700,
the most frequent gene responsible localized to Xp 22.3
region), autosomal-dominant (KAL-2, OMIM 147950),
and autosomal-recessive (KAL-3, OMIM 244200). The
encoded protein was named anosmin-1 in reference to
the defective sense of smell characterizing the disease.
The presence of anosmin-1 in the inner ear structures at
early developmental stages suggests that the defect un-
derlying the hearing loss in X-linked Kallmann syndrome
occurs during organogenesis. Moreover, the regional dis-
tribution of the protein argues against a direct role in the
differentiation of the cochlear sensory epithelium. The
observation that anosmin-1 is produced in the urinary
system from the early steps of nephrogenesis strongly
suggests that the renal aplasia in X-linked Kallmann syn-
drome results from actual agenesis of the metanephros
and not from degeneration after the organogenesis pe-
riod. Moreover, the restriction of the protein to the
collecting duct system argues in support of the absent
development or early degeneration of this system (which
is normally required for induction of the metanephro-
genic mesenchyme) as the primary defect. This is
further supported by the absence of the vas deferens ipsi-
lateral to the missing kidney, which has been observed in
a few affected individuals [90, 91]. This anomaly results
from the degeneration of the mesonephric duct (from
which the ureteric bud is derived), a structure that also
produces anosmin-1. A direct role of anosmin-1 in the
reciprocal mesenchymal-epithelial interactions between
the renal blastema and ureteric branches appears unlikely
since, at any studied stage, anosmin-1 was only detected in
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proximal segments of the ingrowing ureteric arborization
and not in the distal branches which are induction sites.
Finally, the incomplete penetrance of the renal aplasia in
X-linked Kallmann syndrome, which does not exceed one
out of two or three cases [90], as well as the presence of
one functional kidney in affected individuals, both indi-
cate that other molecules can compensate for anosmin-1
deficiency in kidney organogenesis. Hearing loss has been
reported in many individuals affected by Kallmann syn-
drome [92] and, more recently, in several authenticated
X-linked cases of the disease [89]. In most affected indi-
viduals, the hearing loss is described as bilateral and per-
ceptive but also as conductive hearing loss [93]. However,
detailed functional and morphologic investigations have
been reported in only a small number of patients and,
thus far, in not individual with authentificated X-linked
Kallmann syndrome. Very recently, Dode et al [24] re-
ported that a second gene has been recently identified
that encodes for FGFR-1. The authors established that
loss-of-function mutations in FGFR-1 underlie KAL-2
whereas a gain-of-function mutation in FGFR-1 has been
shown to cause a form of craniosynostosis. Moreover, the
authors suggest that the KAL-1 gene product, the ex-
tracellular matrix protein anosmin-1, is involved in FGF
signaling and propose that the gender difference in
anosmin-1 dosage explains the higher prevalence of the
disease in males.
Renal tubular disturbance and sensorineural deafness
Bartter syndrome. Renal salt loss in Bartter syndrome
is caused by impaired transepithelial transport in the loop
of Henle. Sodium chloride is taken up apically by the com-
bined activity of NKCC2 (Na+-K-−2 Cl− cotransporters)
and ROMK potassium channels. Chloride ions exit from
the cell through basolateral ClC-Kb chloride channels.
Mutations in the three corresponding genes have been
identified [50–52] that correspond to Bartter syndrome
types 1 to 3. A gene locus of a fourth variant of ante-
natal BS called BSND (Bartter with sensorineural deaf-
ness), which in contrast to the other forms is associated
with sensorineural deafness (SND) and renal failure, has
been mapped to chromosome 1p [94] and has resulted in
new insights into renal salt handling, diuretic action and
blood-pressure regulation [95, 96]. Positional cloning of
the Bartter sensorineural deafness (BSND) gene, which
underlies Bartter syndrome type 4 (also named BSND;
OMIM 602522), identified barttin (OMIM 606412). In
situ hybridization showed barttin expression in specific
nephron segments and in the stria vascularis [95]. Barttin
forms heteromers with ClC-K1 (ClC-Ka) in the thin as-
cending limb of Henle [97] and with ClC-K2 (ClC-Kb) in
the thick ascending limb and more distal segments [98].
Barttin was also detected in basolateral membranes of in-
tercalated cells of the collecting duct, which are known to
express ClC-K2 (ClC-Kb) as well [98]. In the inner ear,
barttin colocalized with ClC-K in K+ secreting marginal
cells of the stria vascularis. The basolateral staining for
both proteins contrasts with the apical localization of the
KCNQ1 K+ channel. Barttin was also found in K+ se-
creting vestibular dark cells, where it colocalizes in baso-
lateral membranes with ClC-K below apical membranes
that express KCNQ1. In the kidney, ClC-K/barttin het-
erodimers mediate Cl− reabsorption by facilitating its ba-
solateral efflux. In the stria, ClC-K/barttin channels drive
K+ secretion by recycling Cl− for the basolateral NKCC1
cotransporter. This role is analogous to that of ROMK in
Cl− reabsorbing cells of the thick ascending limb, where
it recycles K+ for the apical NKCC2 cotransporter. Bart-
tin acts as an essential b-subunit for ClC-Ka and ClC-Kb
chloride channels, with which it colocalizes in basolateral
membranes of renal tubules and of potassium-secreting
epithelia of the inner ear. Disease-causing mutations in
either ClC-Kb or barttin compromise currents through
heteromeric channels. ClC-Ka and ClC-Bb are higly ho-
mologous chloride channels that are nearly exclusively
expressed in kidney. CLCNKB mutation in Bartter syn-
drome [99] together with immunohistochemical results
[98, 100] suggest that human ClC-Kb (the ortholog of ro-
dent ClC-K2) mediates basolateral chloride efflux in the
thick ascending limb of Lembe’s loop and in more dis-
tal nephron segments. Similarly, immunolocalization [95]
and the diabetes insipidus observed in Clcnk1−/− mice
[101] indicate that rodent ClC-K1 (the ortholog of hu-
man CC-Ka) is crucial for transepithelial transport in the
thin ascending limb. Because barttin is crucial for ClC-Kb
function, its inactivation results in renal salt wasting as
do mutations in ClC-Kb [102]. However, because bart-
tin also associates with ClC-Ka, additional symptoms are
expected. These may resemble the diabetes insipidus-
like phenotype observed in Clcnk1−/− mouse [101]. In-
deed, BSND patients present with more severe renal
symptoms than patients having mutations in ClC-Kb
[95, 103]. Unlike mutations in barttin [104], mutations
in the ClC-Kb b-subunit [99] do not cause deafness, nor
was deafness described in mice disrupted for ClC-K1
[101].
Renal tubular acidosis with progressive nerve deafness
(267300). Primary distal renal tubular acidosis (dRTA)
type I is a hereditary renal tubular disorder, which is char-
acterized by impaired renal acid secretion resulting in
metabolic acidosis. Clinical symptoms are nephrocalci-
nosis, nephrolithiasis, osteomalacia, and growth retarda-
tion. Biochemical alterations consist of hyperchloremic
metabolic acidosis, hypokalemia with muscle weakness,
hypercalciuria, and inappropriately raised urinary pH.
Autosomal-dominant and rare forms of recessive dRTA
(rdRTA) are known to be caused by mutations in the
gene for the anion exchanger AE1. Two types of rdRTA
have been differentiated by the presence or absence of
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sensorineural hearing loss, but appear otherwise clinically
similar. A large proportion of autosomal-recessive dis-
tal renal tubular acidosis (RTA) is associated with mu-
tations in the ATP6B1 gene (192132) encoding the B1
subunit of H(+)-ATPase [105]. H(+)-ATPase is one of
the key membrane transporters for net acid excretion in
the a-intercalated cells of the medullary collecting duct
and was mapped to 2cen-q13. Sensorineural hearing loss
frequently accompanies this type of distal RTA. Karet
et al [106] demonstrated that distal renal tubular acidosis
with sensorineural hearing loss (dRTA) is caused by mu-
tations in the ATP6B1 gene, which encodes the B subunit
of the apical proton pump mediating distal nephron acid
secretion. Consistent with the associated hearing loss,
Karet et al [106] demonstrated expression of ATP6B1 in
the cochlea and endolymphatic sac. This demonstration,
together with the known requirement for active proton
secretion to maintain proper endolymph pH, implicated
ATP6B1 in endolymph pH homeostasis and in normal au-
ditory function. The authors studied the dRTA syndrome
in four outbred kindreds with two or more affected sibs
and in 27 kindreds with parental consanguinity, of which
seven had more than one affected individual. Of the 27
consanguineous kindreds, parents were first cousins in 20
and more distantly related in the remainder. All index
cases were diagnosed by 6 years of age, with 19 diag-
nosed by 1 year of age. They presented either acutely
with dehydration and vomiting, or with failure to thrive
and/or growth impairment. In each case, the diagnosis
was based on inappropriately alkaline urine (pH greater
than 5.5) and the presence of systemic metabolic acido-
sis with normal anion gap, evidence of renal potassium
wasting, and no evidence of secondary causes of dRTA.
All patients had nephrocalcinosis, accompanied by ele-
vated urinary calcium. Rickets was also noted in five of
these kindreds. Despite the nephrocalcinosis, renal func-
tion was otherwise normal in every case, and remained
so in all but one female who developed end-stage re-
nal disease at 18 years of age; the median follow-up was
5 years (range 0.5 to 40). All patients had normal serum
sodium, calcium, phosphate, creatinine, and magnesium.
Bilateral sensorineural hearing loss was found in 15 af-
fected subjects from 10 kindreds. The hearing loss varied
in severity from mild (40 dB) to profound (100 dB). In
20 subjects from 15 kindreds, audiometry excluded a sen-
sorineural deficit. Significantly, hearing status in all 10
tested sib pairs or trios with dRTA was concordant, sug-
gesting that the occurrence of hearing impairment was
not stochastic among affected patients.
Mutations in the gene encoding the apical pump
ATP6B1 cause dRTA accompanied by deafness. How-
ever, ATP6N1B mutations, which were expressed exclu-
sively to the apical surface of -intercalated cells in the
kidney but not other main organs, do not cause deafness
[107].
Hypophosphatemia, hereditary, type II, or hypophos-
phatemic D–resistant rickets II; HPDR II; HYP2; Gyro
equivalent; Gy equivalent (307810). In the mouse, Lyon
et al [108] identified a second type of X-linked dominant
hypophosphatemia. The mutation, called Gyro (Gy), is
manifested by rickets/osteomalacia as in the Hyp muta-
tion (307800) but in addition shows circling behavior, in-
ner ear abnormalities, sterility in hemizygous males, and
a milder phenotype in heterozygous females. The Gy and
Hyp mutations have similar expression in the renal tubule
but the Gy mutation has an additional effect on the inner
ear. The nature of the translation product that is com-
mon to the inner ear and renal brush-border membrane
is unknown. The Gy allele is expressed in the inner ear of
some heterozygous mice, which show circling behavior.
Deafness has been reported in humans with X-linked hy-
pophosphatemia [109, 110] but has been observed also in
the autosomal-recessive form of hypophosphatemic rick-
ets [111]. It is likely that an X-linked human homologue
of the mouse Gy mutation will be identified. That there
are at least two forms of X-linked hypophosphatemia de-
termined by genes on Xp11.22 is indicated by the fact
that causative mutations have been found both in the
HYP gene, also known as PEX (307800), which has ho-
mologies to the endopeptidases and in the CLCN5 gene
(300008) [112]. Strom et al [113] cloned the mouse ho-
mologue of the PEX gene, which was known to be the
site of mutations causing hereditary hypophosphatemia
in the human. They found a high degree of conservation
between man and mouse.
Glomerular disease and deafness
Alport syndrome. Alport syndrome, a hereditary
basement membrane disease affecting approximately
one in 5000 people, is a disorder of type IV collagen
with progressive nephropathy, ocular abnormalities, and
high-tone sensorineural deafness. In X-linked Alport syn-
drome, mutations in the COL4A5 gene encoding the a5
chain of type IV collagen lead to loss of the a3/a4/a5
network and increased susceptibility of the glomerular
basement membrane to long-term damage. No effective
drug therapy exists for the disease, which is currently
treated by dialysis and renal transplant [114, 115]. The
classic phenotype as described by Alport [116] affected
both genderss in successive generations. The renal dis-
ease becomes evident as recurrent microscopic or gross
hematuria as early as childhood, earlier in males than
in females. Nephrotic syndrome, although unusual, has
been reported. The most common form of the disease is
X-linked, and caused primarily by mutations in the colla-
gen a5(IV) gene [117], accounting for ∼ 80% of the cases.
Mutations in the collagen a3(IV) or a4(IV) genes lead to
the recessive forms of the diseases [118, 119]. The absence
of any one of these type IV collagen chains can result in
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the absence of all three chains in the glomerular basement
membrane, presumably due to an obligatory association
of the three chains in forming the type IV collagen su-
perstructure [119, 120]. Normal distribution of the three
a chains is observed in approximately one third of pa-
tients [121]. Expansion of the mesangial matrix occurs
early in Alport renal pathogenesis. Hearing loss, which
is sensorineural and primarily affects high tones, occurs
in 30% to 50% of relatives with renal disease. The sever-
ity of auditory and renal features does not correlate in a
given individual. The molecular defects that underlie the
otopathology in this disease remain poorly understood.
Using a canine model of X-linked Alport syndrome to
determine the expression of type IV collagen a chains
in the inner ear, Harvey et al [122] show that affected
dogs have complete absence of the a3/a4/a5 network.
The lateral aspect of the spiral ligament is populated by
tension fibroblasts that express a-smooth muscle actin
and nonmuscle myosin and are postulated to generate
radial tension on the basilar membrane via the extracel-
lular matrix for reception of high frequency sound. The
authors propose that in Alport syndrome, the loss of the
a3/a4/a5 network eventually weakens the interaction of
these cells with their extracellular matrix, resulting in re-
duced tension on the basilar membrane and the inability
to respond to high frequency sounds. Demonstration of
linkage analysis to chromosome 2q in consanguineous
families and of mutations in one or the other of these
two autosomal genes provided clear evidence of the ex-
istence of the autosomal recessive form of Alport syn-
drome. It remained to be determined whether mutations
in either of these genes in heterozygous state cause abnor-
mality. Jefferson et al [123] mapped autosomal-dominant
Alport syndrome in a single family to chromosome 2, in
the vicinity of COL4A3 and COL4A4. Furthermore, in
the autosomal-dominant Alport syndrome, a splice-site
mutation resulting in skipping of exon 21 of the COL4A3
gene was detected by van der Loop et al [124].
Fechtner syndrome. The first study reports by Peterson
in a family comprising four generations in whom nephri-
tis, deafness, congenital cataracts, macrothrombocytope-
nia, and leukocyte inclusions were observed in varying
combinations in eight of 17 members [125]. Fechtner
syndrome (FTNS) is a rare inherited condition char-
acterized by progressive nephritis (39%), macrothrom-
bocytopenia (100%), Dohle-like leukocyte inclusions
(100%), deafness (49%), and cataract (54%). Deafness
was high-tone sensorineural. Renal disease ranged from
microscopic hematuria to end-stage renal failure neces-
sitating dialysis and kidney transplantation. Although it
recently was shown that FTNS derives from mutation of
MYH9, the gene for the heavy chain of nonmuscle myosin
IIA (NMMHC-IIA) [126]. Hearing loss in Fechtner syn-
drome appears to be sensorineural with the higher fre-
quencies primarily affected. The most striking difference
between hearing loss in Fechtner syndrome and that in
Alport syndrome was that the vast majority of hearing
disorders in the latter occur in male patients, which is not
the case in Fechtner syndrome. Hearing loss in Fecht-
ner syndrome develops from the second decade of life
and progresses slowly with several episodes of sudden
deafness [127]. Renal biopsy findings are consistent with
those of Alport syndrome, and the associated renal dis-
ease is said to be unusual before middle to late adult-
hood. Chronic renal failure can occur at a young age in
patients with Fechtner syndrome, with a possible rela-
tion to race/ethnicity. Fechtner syndrome, or variants of
Alport syndrome, should be considered in patients pre-
senting with proteinuria and thrombocytopenia [128].
Because of the phenotypic similarities between
May-Hegglin anomaly and Fechtner syndrome and the
demonstration that the two disease loci are mapped
to overlapping regions on chromosome 22, the May-
Hegglin/Fechtner Syndrome Consortium (2000) sug-
gested that they, as well as Sebastian syndrome, might be
allelic. MYH9 was a strong candidate gene because it is
located within that region of chromosome 22, is expressed
in platelets, and is upregulated during granulocyte
differentiation.
PERSPECTIVES
We have described ear and kidney clinical syndromes
and their molecule expression. Furthermore, other gene
or transcription factors are responsible for physiologic
symptoms in one or both organs but without yet discribed
clinical syndromes. These pathologies are described in the
following paragraphs.
First, Pendred syndrome (PDS) (274600), the most
common syndromal form of congenital deafness, is an
autosomal-recessive disorder associated with develop-
mental abnormalities of the cochlea, fluctuating and
progressive sensorineural hearing loss, and goiter. This
syndrome was described by Vaughan Pendred [129]. It
was exactly a century later that Coyle et al [130] and
Sheffield et al [131] showed that the disorder maps to
chromosome 7q (22-q31). The Solute Carrier Family 26,
Member 4; (SLC26A4) (605646) gene encodes an anion
transporter known as pendrin (OMIM 605646) and is
the gene mutant in PDS (274600), DFNB4 (600791), and
enlarged vestibular aqueduct syndrome (EVA) (603545)
[132]. Pendrin is an anion transporter encoded by the
Pendrin Syndrome (PDS/Pds) gene. Labeling was de-
tected on the apical surface of a subpopulation of cells
within the cortical collecting ducts that also express the
H+-ATPase but not aquaporin-2 (AQP-2), indicating that
pendrin is present in intercalated cells of the cortical col-
lecting ducts. Furthermore, pendrin was detected exclu-
sively within the subpopulation of intercalated cells that
express the H+-ATPase but not the AE1 and that are
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thought to mediate bicarbonate secretion. The same dis-
tribution of pendrin was observed in mouse, rat, and hu-
man kidney. RNA in situ hybridization studies revealed
that Pds is expressed in discrete areas of the mouse in-
ner ear, including regions thought to play a key role in
fluid transport [133]. Pendrin directly mediates the trans-
port of bicarbonate across the apical membrane of inter-
calated cells. Pendrin is capable of chloride/bicarbonate
exchange [134]. An alternate explanation is that pendrin
might play an indirect role in apical bicarbonate trans-
port in intercalated cells [135]. Neither PDS patients nor
pendrin-deficient mice have been reported to develop
overt acid-base disturbances, such as a metabolic alka-
losis. This likely reflects the fact that the kidney has other
means of regulating bicarbonate excretion in the absence
of pendrin (e.g., by regulation provided by the Na+/H+
exchanger NHE3 in the proximal tubule and the loop
of Henle [136]). However, there is no yet clinical corre-
sponding pathology in humans.
Second, KCNQ genes encode a growing family of six
transmembrane domains, single pore-loop, K(+) channel
a subunits that have a wide range of physiologic corre-
lates. Mutations in the channel KCNQ1 can cause one
form of inherited long QT syndrome (LQT1), as well as
being associated with a form of deafness. KCNQ2 and
KCNQ3 heteromultimers mutations may cause an inher-
ited form of juvenile epilepsy. The KCNQ4 gene encoding
to the potassium concentration in outer hair cells of the
cochlea and in type I hair cells of the vestibular appara-
tus, mutations in which lead to a form of inherited deaf-
ness, and possibly, mutations in KCNQ5 lead to a form
of inherited retinal degeneration (KCNQ5) [137]. Hear-
ing depends on a high K(+) concentration bathing the
apical membranes of sensory hair cells. K(+) that has en-
tered hair cells through apical mechanosensitive channels
is transported to the stria vascularis for re-secretion into
the scala media. K(+) probably exits outer hair cells by
KCNQ4 K(+) channels, and is then transported by means
of a gap junction system connecting supporting Deiters’
cells and fibrocytes back to the stria vascularis. Mice lack-
ing the K(+)/Cl(−) (K-Cl) cotransporter Kcc4 are deaf
because their hair cells degenerate rapidly after the be-
ginning of hearing. In the mature organ of Corti, Kcc4 is
restricted to supporting cells of outer and inner hair cells.
Similar to some human genetic syndromes, deafness in
Kcc4-deficient mice is associated with renal tubular aci-
dosis. It probably results from an impairment of Cl(−) re-
cycling across the basolateral membrane of acid-secreting
a intercalated cells of the distal nephron [138].
Third, in the kidney, at least seven aquaporins are ex-
pressed at distinct sites. AQP-2 is exclusively expressed in
the principal cells of the connecting tubule and collecting
duct and is the predominant vasopressin-regulated water
channel. Body water balance is tightly regulated by vaso-
pressin, and multiple studies now have underscored the
essential roles of AQP-2 in this. Vasopressin regulates
acutely the water permeability of the kidney collecting
duct by trafficking of AQP-2 from intracellular vesicles
to the apical plasma membrane. Lack of functional AQP-
2 is seen in primary forms of diabetes insipidus, and
reduced expression and targeting are seen in several dis-
eases associated with urinary concentrating defects such
as acquired nephrogenic diabetes insipidus, postobstruc-
tive polyuria, as well as acute and chronic renal failure. In
contrast, in conditions with water retention such as severe
congestive heart failure, pregnancy, and syndrome of in-
appropriate antidiuretic hormone secretion, both AQP-2
expression levels and apical plasma membrane targetting
are increased, suggesting a role for AQP-2 in the devel-
opment of water retention [139]. AQP-2 is expressed in
the cochlea, testis, and kidney and an absence of tissue-
specific splice variants. The level of AQP-2 transcript in
the cochlea was tenfold lower relative to its expression
in the testis and kidney. In the rat and mouse cochlea,
AQP-2 was expressed in the structures bordering the en-
dolymph, including Reissner’s membrane, the organ of
Corti, inner and outer sulcus cells and the spiral lim-
bus. The physiologic role of AQP-2 in water transport
and its expression pattern in the cochlea suggests an im-
portant role for AQP-2 in fluid homeostasis of the in-
ner ear [140]. Nephrogenic diabetes insipidus, which can
be inherited or acquired, is characterized by an inability
to concentrate urine despite normal or elevated plasma
concentrations of the antidiuretic hormone arginine va-
sopressin. Polyuria, with hyposthenuria, and polydipsia
are the cardinal clinical manifestations of the disease.
About 90% of patients with congenital nephrogenic dia-
betes insipidus are males with the X-linked recessive form
of the disease (OMIM 304800) who have mutations in
the arginine vasopressin receptor 2 gene (AVPR2), which
encodes for the vasopressin V2 receptor. The gene
is located in chromosomal region Xq28. In <10%
of the families studied, congenital nephrogenic dia-
betes insipidus has an autosomal-recessive or autosomal-
dominant (OMIM 222000 and 125800, respectively)
mode of inheritance. Mutations have been identified in
the aquaporin-2 gene (AQP2), which is located in chro-
mosome region 12q13 and encodes for the vasopressin-
sensitive water channel [141, 142].
Finally, kidney and inner ear have specialized epithe-
lia involved in active ion transport, which are separated
from the vessels by a basement membrane of similar com-
position. Meyer, Balz, and Felix [143] indicate that the
glomerular and the stria vascularis basement membrane
are simultaneously affected in early stages in the Mpv17-
negative mouse strain. Concomitant deposits of IgG dur-
ing the progressive development of the disease support
the idea of a shared antigen.
The Mpv17 mouse strain is a recessive transgenic
mouse mutant that develops glomerulosclerosis and
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nephrotic syndrome at a young age. These revealed de-
generation of the stria vascularis and spiral ligament, loss
of cochlear neurons and degeneration of the organ of
Corti [144]. The alterations observed here were similar
to those described for Alport syndrome. These findings
indicate that, although the molecular cause is different,
the Mpv17 mouse model may share pathologic mecha-
nisms involved in patients with Alport syndrome [144].
CONCLUSION
Ear and kidney development have been characterized
in great detail, and we now know that embryologically,
ear and kidney primordia arise at different times and de-
velop at different rates. Gene expression studies allow
a better understanding of ear and kidney clinical syn-
drome. A careful analysis of those clinical manifestations
will also help us in the comprehension of ear and kidney
development.
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